Sorafenib also sustains remission in AML patients harbouring FLT3-ITD mutations following allogenic stem cell transplant [163,164] and a Phase IV trial is currently underway to investigate this further (NCT02474290). The gene discussed is FLT3; the disease is acute myeloid leukemia.